I have a soft spot for fibroblasts, perhaps because one of the first immortalized cell lines I ever grew was NIH3T3. These are mouse fibroblasts that have been immortalized. They are very useful for a variety of experiments. I used them to study an oncogene called E2A-PBX1. Experience with fibroblasts including 3T3s I was amazed […]
Weekly reads: fibroblasts, gene-editing, Mitalipov, personhood, embryos Read More »
Remember that Shoukhrat Mitalipov lab paper on the use of CRISPR in human embryos? It’s back in the news. One of the biggest stories of 2017 centered on a Nature paper (Ma, et al., see my quick, initial review shortly after it was published here) from Mitalipov’s lab claiming both efficient repair of a disease-causing
Mitalipov rebuts CRISPR pub critiques: strengthens case, but puzzles remain Read More »
The debate over whether the main conclusions of the Nature paper on human embryo CRISPR led by Shoukhrat Mitalipov’s lab at Oregon Health Sciences University (OHSU) are correct remains unresolved. Note that Nature just added an editorial alert just above the references section to their paper: “Updated online 02 October 2017. Editorial Note: Readers are alerted that some
Why Mitalipov’s ‘magic’ room for human embryo CRISPR may give us pause Read More »
What really happened at the DNA level in the experiments in that high-profile CRISPR of human embryos paper from a team led by Shoukhrat Mitalipov at OHSU? Is the team right that they successfully conducted CRISPR of human embryos to correct a mutant gene, as they reported in their Ma, et al. Nature paper? Or is the Egli,
Mulling over that Mitalipov human embryo CRISPR pub, still many questions Read More »
There has been a wave of intense discussions both in the public domain such as on Twitter and behind the scenes over the new Egli, et al. preprint that challenges the main conclusions of the Ma, et al. Nature paper from Shoukhrat Mitalipov’s lab. Ma, et al. reported CRISPR gene editing of human embryos, arguing for
Mitalipov briefly responds to Egli preprint, stands by human embryo CRISPR pub findings Read More »
We can be confident that human genetic modification via CRISPR’ing of embryos soon will be safe and effective after that new exciting Mitalipov team paper, right? Wrong. The reality is far more complicated and interesting on the tech side. In a nutshell, I see the paper as a significant scientific, but not necessarily medical advance.
4 key reasons Mitalipov paper doesn’t herald safe CRISPR human genetic modification Read More »
In the same way perhaps that some excited relatives or parents-to-be both gush and worry about a baby before it is even born, our field has been transfixed for a week by the Mitalipov paper on CRISPR’ing human embryos even though the paper just now came out. Now that the paper is out, we can
Review of Mitalipov paper CRISPR’ing human embryos: transformative work on the edge Read More »
The human embryo CRISPR paper with Shoukhrat Mitalipov as senior author is coming soon. It will reportedly be focused on the use of CRISPR to genetically modify viable human embryos for reversal of a disease-associated mutation. While strangely press already broke early on this paper last week, as much as a week before the paper
Big 5 questions anticipating Mitalipov human embryo CRISPR paper Read More »
The new CRISPR human embryo paper from Shoukhrat Mitalipov is stirring things up, but then there’s also the murky back story as to how the news of this as yet unpublished paper got leaked in the first place. The actual paper is still not out and from what I understand hasn’t even been officially released
Who leaked Mitalipov CRISPR human embryo paper? Read More »
More CRISPR’d human embryos, but this time in America? MIT Tech Review is reporting that Oregon scientist Shoukhrat Mitalipov has used CRISPR on human embryos in his lab in the US. Apparently a paper is in the works on this. While details are sketchy and some specifics remain to be clarified to be sure of
In first for U.S., Mitalipov reportedly CRISPR’d human embryos & it was great Read More »